PPARG and obesity due to melanocortin 4 receptor deficiency: This approach not only accelerates the identification of safer, tissue-selective PPARγ modulators but also bridges traditional pharmacopeias with modern structure-based drug design, offering a sustainable strategy to combat obesity-related metabolic disorders.